News

WebMD1mon
Your Guide to Turalio for Tenosynovial Giant Cell Tumor
Giant cell tumors of the tendon sheath (GCTTS ... There is a patient support program, Daiichi Sankyo Access Central, that may help you afford Turalio. Your health care provider will help you ...
Mirage News5d
Pimicotinib Shows Top Efficacy in Giant Cell Tumor
Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate ...
Monthly Prescribing Reference3mon
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...
New York Post4mon
I had a one-in-a-million tumor eating my bones — the signs that made me beg doctors to see me
Looking at the scan, the doctor told her he believed she had a “very big” giant cell tumor. “He said, ‘Yeah, it’s pretty rare, but when we find one, they’re massive. We got to get this ...
Monthly Prescribing Reference1mon
Emactuzumab Fast Tracked for Tenosynovial Giant Cell Tumor
Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
Medscape3mon
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...
Cure Today1mon
Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors
Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...
MedPage Today3mon
Second Drug for Benign Synovial Tumor Condition Wins FDA Approval
The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant, but debilitating, condition arising in ...
Yahoo Finance3mon
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...
WebMD3mon
FDA Approves New Drug for Rare Joint Tumor
Feb. 18, 2025 — The FDA has approved vimseltinib, a new oral drug for a rare, noncancerous tumor of the joints known as tenosynovial giant cell tumor (TGCT). It is intended for adults with ...